U
FOLD

UBS’s Amicus Therapeutics FOLD Stock Holding History

UBS’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$101K Hold
17,000
– – ﹤0.01% 5981
2014
Q2 		$57K Buy
17,000
+2,000
+13% +$4.7K ﹤0.01% 6692
2014
Q1 		$31K Sell
15,000
-1,993
-12% -$4.98K ﹤0.01% 7480
2013
Q4 		$40K Sell
16,993
-7
-0% -$15 ﹤0.01% 7250
2013
Q3 		$39K Buy
17,000
+1,000
+6% +$2.51K ﹤0.01% 7169
2013
Q2 		$37K Buy
+16,000
New +$49.2K ﹤0.01% 7126

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

UBS's FOLD Position: Q3 2014 in Review

UBS held its Amicus Therapeutics (FOLD) position steady in Q3 2014 at 17,000 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #5981.

UBS first reported a position in FOLD in Q2 2013 and has held it in 6 quarters since. 95 funds tracked by Wall St. Rank hold FOLD as of Q3 2014.

  • UBS held 17,000 shares of Amicus Therapeutics worth $101K as of Q3 2014.
  • UBS left its Amicus Therapeutics share count unchanged in Q3 2014.
  • Amicus Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5981 holding.
  • UBS first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • 95 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.